A Phase II/III Study of Peginterferon Alfa-2a in Combination With Ribavirin for the Treatment of CHC With Compensated LC.

Trial Profile

A Phase II/III Study of Peginterferon Alfa-2a in Combination With Ribavirin for the Treatment of CHC With Compensated LC.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 May 2016

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 10 May 2011 Results presented at Digestive Disease Week 2011.
    • 02 Jun 2010 Actual end date (June 2010) added as reported by ClinicalTrials.gov.
    • 02 Jun 2010 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top